174 related articles for article (PubMed ID: 18349409)
1. Multiple myeloma with testicular involvement.
Hwang YY; Chim CS; Shek TW
J Clin Oncol; 2008 Mar; 26(9):1558-9. PubMed ID: 18349409
[No Abstract] [Full Text] [Related]
2. Optimising bortezomib in newly diagnosed multiple myeloma.
Rajkumar SV
Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
[No Abstract] [Full Text] [Related]
3. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
[No Abstract] [Full Text] [Related]
4. [Analysis of Bortezomib-containing combinations in newly-diagnosed multiple myeloma patients: a comparative study].
Xu L; Qiu H; Hu X; Lyu S; Song X; Chen L; Zhang W; Gao L; Xu X; Wang J; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):448-50. PubMed ID: 24857218
[No Abstract] [Full Text] [Related]
5. [Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Wang LX; Lu H; Shen WY; Qian SX; Qiu HX; Wu HX; Zhang JF; Wu YJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):943-5. PubMed ID: 18718096
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-induced acute congestive heart failure: a case report and review of literature.
Subedi A; Sharma LR; Shah BK
Ann Hematol; 2014 Oct; 93(10):1797-9. PubMed ID: 24599584
[No Abstract] [Full Text] [Related]
7. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Bernardeschi P; Pirrotta MT; Montenora I; Giustarini G; Ferreri MI; Simi P; Fiorentini G
Leuk Res; 2010 Apr; 34(4):e104-5. PubMed ID: 19889456
[No Abstract] [Full Text] [Related]
8. Bortezomib plus melphalan and prednisone for multiple myeloma.
Avvisati G
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
[No Abstract] [Full Text] [Related]
9. Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R; Cibeira MT; Uriburu C; Yantorno S; Salamero O; Bladé J; Montserrat E
Eur J Haematol; 2006 May; 76(5):405-8. PubMed ID: 16529604
[TBL] [Abstract][Full Text] [Related]
10. [Modified bortezomib-based combination therapy for multiple myeloma].
Wei D; Zhao C; Zhao M; Wei J; Gao Y; Cai Q; Wang C
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):854-6. PubMed ID: 25246260
[No Abstract] [Full Text] [Related]
11. Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Sadek I; Dispenzieri A; Gertz MA; Kumar S
Leuk Lymphoma; 2009 Jun; 50(6):1033-5. PubMed ID: 19455462
[No Abstract] [Full Text] [Related]
12. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
13. Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Nizeica V; Collet P; Marotte H
Ann Hematol; 2013 Aug; 92(8):1135-6. PubMed ID: 23370597
[No Abstract] [Full Text] [Related]
14. RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D; Armenteros E; Percy L; Kumar M; Lach A; Herledan G; Stubbs M; Downward J; Yong K
Br J Haematol; 2015 Jun; 169(6):905-8. PubMed ID: 25580780
[No Abstract] [Full Text] [Related]
15. [Multiple myeloma--recent advances in diagnosis and treatment].
Chou T
Gan To Kagaku Ryoho; 2005 Mar; 32(3):304-8. PubMed ID: 15791813
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myeloma--are we making progress?
Durie BG
N Engl J Med; 2008 Aug; 359(9):964-6. PubMed ID: 18753654
[No Abstract] [Full Text] [Related]
18. [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Szturz P; Jakubcová R; Adam Z; Klincová M; Krejcí M; Pour L; Zahradová L; Hájek R; Mayer J
Klin Onkol; 2011; 24(3):216-20. PubMed ID: 21717791
[TBL] [Abstract][Full Text] [Related]
19. [The clinical study on treatment with bortezomib for multiple myeloma].
Chen C; Zhao CL; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):265-7. PubMed ID: 21569711
[No Abstract] [Full Text] [Related]
20. Incorporating monoclonal antibodies into the therapy of multiple myeloma.
Bladé J; de Larrea CF; Rosiñol L
J Clin Oncol; 2012 Jun; 30(16):1904-6. PubMed ID: 22291081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
